Advance one bounded pharmaceutical or diagnostic process region, scale-up, site schedule, lifecycle comparison or regulated change only after product quality, patient-relevant controls, equipment fit, finite resources, economics, environmental inventory and evidence remain explicit.
Independent hypothetical company study · pharmaceuticals and diagnostics
RocheFive process decisions
Choose one use case. Add authorised plant data. Test capacity, cost and constraints.
Decision brief
One question. One model.
One authorised medicine, assay or anonymised product family and one declared development, manufacturing, diagnostics or change boundary, including materials, reagents, unit operations, equipment, utilities, cleaning, laboratories, release, waste and relevant handoffs.
Five practical use cases
Five places to start.
Evaluation scopes for Roche—not claims of current software use.Prioritise a pharmaceutical or diagnostic experiment
Compare one authorised material, reagent, biological, purification, formulation or diagnostic-unit-operation region against the same CQA, CPP, assay, robustness and uncertainty basis before selecting the next laboratory or pilot series.
Screen pilot-to-site facility fit
Map approved development evidence to one current, authorised receiving process chain, comparing kinetics, mixing, transfer, hold, utilities, sterility, containment, cleaning and laboratory envelopes while flagging open engineering, quality and validation work.
Schedule manufacturing, laboratory and release resources
Sequence anonymised products or tests across equipment, lines, cleaning, materials, laboratories, maintenance, sampling and release holds without representing actual Roche occupancy, bottlenecks, capacity, supply commitments or patient demand.
Compare product-system TEA/LCA pathways
Evaluate one process, equipment, packaging, cold-chain or logistics alternative under a fixed functional unit and quality function, separating yield, materials, solvents, utilities, consumables, waste, transport, cost and inventory uncertainty.
Govern regulated change and transfer evidence
Link one change ID to its CQA/CPP and assay baseline, materials, methods, comparability, characterisation, validation planning, system versions, deviations, risks and criteria while leaving every quality, regulatory, PPQ and release approval outside the model.
Action pack
Inputs in. Decisions out.
- Authorised product, material or reagent, process, CQA/CPP and demand basis
- Development, scale-down, analytical, assay and equipment evidence
- Equipment eligibility, routings, cleaning, maintenance, QC and release rules
- Materials, consumables, utilities, packaging, logistics, cost and lifecycle factors
- Pharmaceutical or diagnostic experiment comparison
- Pilot-to-site equipment-fit evidence map
- Finite manufacturing, laboratory and release schedule
- TEA/LCA screen and regulated-change evidence register
- Select one authorised development, transfer, schedule or change decision.
- Declare the programme, legal entity, division, current site and evidence boundaries.
- Import approved development, analytical, equipment and quality evidence.
Evidence and limits
Public evidence only.
- Roche — Annual Report 2025Official current legal, divisional, Genentech, Chugai, Poseida, operating and sustainability context.
- Roche — Annual General Meeting 2026Official current group, legal and ownership context including Genentech and Chugai.
- Roche — Half-Year Results 2026Official current portfolio and divisional context and the PathAI acquisition agreement boundary.
- Roche — Share and Bond InformationOfficial current context for Roche Holding Ltd and its capital structure.
- Roche — Sustainable ProductsOfficial context for existing lifecycle, eco-design, Green Chemistry, packaging and product-stewardship capabilities.
- Roche — Sustainability Targets and PerformanceOfficial context for the Product Sustainability Performance tool, lifecycle integration and current environmental targets.
- Roche — Product StewardshipOfficial context for existing information, documentation and environmental-risk processes.
Guardrail: This is an independent hypothetical study based only on public sources. Roche Holding Ltd, Roche Group, its Pharmaceuticals and Diagnostics divisions, Genentech, Chugai, Poseida and their legal entities and brands are not represented as Acatian customers, users, partners or endorsers. No medicine, assay, programme, site, train, schedule, bottleneck, capacity, yield, cost, environmental result, system connection, private data or performance is represented. PathAI is treated only as the subject of an announced acquisition agreement, not a completed Roche acquisition. Acatian would not replace Roche R&D, manufacturing, diagnostics, digital, PSP, LCA, QMS, MES, LIMS, eBR, CMC, regulatory, PPQ, validation or release systems; approved company reviewers retain every regulated and commercial decision.